C-Peptide Is a Sensitive Indicator for the Diagnosis of Metabolic Syndrome in Subjects from Central Mexico
- 1 May 2016
- journal article
- research article
- Published by SAGE Publications in Metabolic Syndrome and Related Disorders
- Vol. 14 (4) , 210-216
Abstract
Background: Metabolic Syndrome (MetS) is associated with elevated risk for developing diabetes and cardiovascular disease. A key component of MetS is the development of insulin resistance (IR). The homeostatic model assessment (HOMA) model can determine IR by using insulin or C-peptide concentrations; however, the efficiency of insulin and C-peptide to determine MetS has not been compared. The aim of the study was to compare the efficiency of C-peptide and insulin to determine MetS in Mexicans. Methods: Anthropometrics, glucose, insulin, C-peptide, triglycerides, and high-density lipoproteins were determined in 156 nonpregnant females and 114 males. Subjects were separated into normal or positive for MetS. IR was determined by the HOMA2 calculator using insulin or C-peptide. Correlations were calculated using the Spearman correlation coefficient (ρ). Differences between correlations were determined by calculating Steiger's Z. The sensitivity was determined by the area under receiver operating characteristics curve (AUC) analysis. Results: : Independent of the MetS definition [Adult Treatment Panel III (ATP III), International Diabetes Federation (IDF), or World Health Organization (WHO)], C-peptide and insulin were significantly higher in MetS subjects ( P < 0.05). C-peptide and insulin correlated with all components of MetS; however, for waist circumference, waist-to-hip ratio, and fasting plasma glucose, C-peptide correlated better than insulin ( P < 0.05). Moreover, C-peptide (AUC = 0.72–0.78) was a better marker than insulin (AUC = 0.62–0.72) for MetS ( P < 0.05). Finally, HOMA2-IR calculated with C-peptide (AUC = 0.80–0.84) was more accurate than HOMA2-IR calculated with insulin (AUC = 0.68–0.75, P < 0.05) at determining MetS. Conclusion: C-peptide is a strong indicator of MetS. Since C-peptide has recently emerged as a biomolecule with significant importance for inflammatory diseases, monitoring C-peptide levels will aid clinicians in preventing MetS.Keywords
This publication has 29 references indexed in Scilit:
- A Comprehensive Review on Metabolic SyndromeCardiology Research and Practice, 2014
- Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006Salud Pública de México, 2010
- The Metabolic Syndrome: A Modern Plague Spread by Modern TechnologyThe Journal of Clinical Hypertension, 2009
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Visceral Fat, Waist Circumference, and BMI: Impact of Race/ethnicityObesity, 2008
- High prevalence of metabolic syndrome in MexicoArchives of Medical Research, 2004
- Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitusThe American Journal of Medicine, 2003
- The dysmetabolic syndromeJournal of Internal Medicine, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998